# UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Source: https://onco.cc/trials/nct06590961/  
OnCo record `nct06590961` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of UBX-303-1 run by Ubix Therapeutics, Inc., now recruiting.

## Summary

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies is a phase 1 interventional study registered as NCT06590961 by Ubix Therapeutics, Inc., with 94 participants planned, started 2025-02-20. Conditions recorded: Relapsed/Refractory B-cell Malignancies. Interventions recorded: UBX-303061.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06590961
- Phase: 1
- Setting: A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
- Sponsor: Ubix Therapeutics, Inc.
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT06590961: https://clinicaltrials.gov/study/NCT06590961

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [UBX-303-1](https://onco.cc/drugs/ubx-303061/)
- companies: [Ubix Therapeutics](https://onco.cc/companies/ubix-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06590961.json